News for Citius Pharmaceuticals, Inc. (CTXR)

PR NewswireCRANFORD, N.J., July 17, 2025 CRANFORD, N.J., July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq:

Citius Oncology (CTOR) successfully raises $9 million through a public offering. The offering includes 6,818,182 shares and warrants priced at $1.32 per

PR NewswireCRANFORD, N.J., July 16, 2025 CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq:

Key Highlights: Citius Pharmaceuticals' subsidiary seals a major distribution deal with Cencora for Lymphir. Analysts project significant potential upsid

PR NewswireCRANFORD, N.J., July 15, 2025 Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch r

Citius Oncology (NASDAQ:CTOR) expands its distribution network with a new agreement with Cencora for LYMPHIRâ„¢. The partnership strengthens market read

Citius Pharmaceuticals regains Nasdaq compliance, ensuring continued listing. Stock rises premarket to $2.13.

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the best hot stocks to buy according to Wall Street analysts. In the middle of June, Citius Oncology, which is an oncology-focused subsidiary of Citius Pharmaceuticals, announced that it is nearing completion of preparations for the commercial launch of LYMPHIR. LYMPHIR is an FDA-approved immunotherapy for the treatment […]

PR NewswireCRANFORD, N.J., June 17, 2025 CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncolo

Citius Oncology (CTOR) aims to commercially launch LYMPHIRâ„¢ in the second half of 2025. The company has ensured a 60-month product shelf life and suff

D. Boral Capital has adjusted its price target for Citius Pharmaceuticals (CTXR), decreasing it from $9 to $6, while maintaining a Buy recommendation for the st

Key Highlights: Citius Pharmaceuticals Inc. (CTXR) launches a strategic direct offering, aiming to raise approximately $6 million through shares and warrant

In recent developments from the stock market, Citius Pharmaceuticals (CTXR) has seen a revision in its price target by analyst Jason Kolbert from D. Boral Capit

PR NewswireCRANFORD, N.J., June 10, 2025 $6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise i

Citius Pharmaceuticals (CTXR) has finalized agreements to sell a total of 4.92 million shares of its common stock, along with short-term warrants for an additio

Citius Pharmaceuticals (CTXR) plans to raise up to $15.8 million through a registered direct offering. The initial offering includes 4,920,000 shares at

On June 9, 2025, Citius Pharmaceuticals (CTXR) remains a focal point for investors as renowned analyst firm D. Boral Capital, led by Jason Kolbert, reiterated i

PR NewswireCRANFORD, N.J., June 9, 2025 Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphomaCRANFORD, N.J., Jun

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), has entered into a distribution services agreement with Cardinal Health (CAH).